Samrat Pharmachem Limited has appointed Divyesh J Shah & Associates as its statutory auditors for a term of five years, subject to the approval of shareholders. The decision was taken by the Board of Directors at its meeting held on July 15, 2026, following the recommendation of the Audit Committee of Directors. The appointment is effective from the conclusion of the 34th Annual General Meeting and will remain in force until the conclusion of the 39th Annual General Meeting.

The disclosure was made to BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation detailed that the firm, with ICAI Firm Registration No. 118227W, will serve as the statutory auditors for the specified duration. The Board meeting, which commenced at 2.00 p.m. and concluded at 3.30 p.m. IST, approved the appointment to ensure continued audit oversight.

Divyesh J Shah & Associates, established in 1998, is a partnership firm registered at 410, Parmeshwari Centre, MMM Road, 80, Mulund (West), Mumbai - 400080. The firm offers professional services including auditing, taxation, and management consultancy to clients across India. Its profile indicates prior experience in statutory bank branch audits, debt syndication, and due diligence for mergers and acquisitions. The firm was also appointed by the Government of Maharashtra in 2012 for state subsidy policy guidance.

The appointment is subject to ratification by the members of the company. The information regarding the new auditors has been made available on the company's official website. The company secretary, Nishant Kankaria, signed the disclosure on July 17, 2026, confirming the Board's decision.

Details of Appointment

Samrat Pharmachem Limited has complied with its disclosure requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, by publishing an extract of its standalone audited financial results for the quarter and year ended March 31, 2026. The company submitted the relevant intimation to the Department of Corporate Services, BSE Limited, on June 4, 2026.

Newspaper Publication Details

The extract of the standalone audited financial results was published as an advertisement in newspapers pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The following table summarises the key publication details:

Regulatory Compliance

The publication was made in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. Copies of the newspaper advertisements were enclosed with the intimation letter submitted to BSE Limited. The submission was signed by Nishant Kankaria, Company Secretary and Compliance Officer of Samrat Pharmachem Limited, with a digital signature dated June 4, 2026.

The filing confirms that Samrat Pharmachem Limited has met its obligations under the applicable SEBI listing regulations with respect to the public dissemination of its audited standalone financial results for the financial year ended March 31, 2026.